Heterogeneity of tumor-induced gene expression changes in the human metabolic network

Nature Biotechnology

Volumn 31, Issue 6, 2013, Pages 522-529

  Hu, Jie ^a   Locasale, Jason W ^b   Bielas, Jason H ^c,d   O'Sullivan, Jacintha ^e   Sheahan, Kieran ^e   Cantley, Lewis C ^f   Heiden, Matthew G Vander ^g,h   Vitkup, Dennis ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^f HARVARD MEDICAL SCHOOL   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER THERAPIES; BIOCHEMICAL REACTIONS; CELLULAR METABOLISM; EXPRESSION PATTERNS; ISOCITRATE DEHYDROGENASE; NEOPLASTIC TRANSFORMATION; NUCLEOTIDE BIOSYNTHESIS; OXIDATIVE PHOSPHORYLATION;

BIOCHEMISTRY; HISTOLOGY; ISOENZYMES; METABOLISM; TUMORS;

GENE EXPRESSION;

FUMARATE HYDRATASE; ISOCITRATE DEHYDROGENASE;

ARTICLE; CANCER GENETICS; CELL METABOLISM; GENE EXPRESSION; GENE MUTATION; GLYCOLYSIS; METABOLIC REGULATION; NUCLEOTIDE METABOLISM; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; UPREGULATION;

CELL TRANSFORMATION, NEOPLASTIC; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; ISOCITRATE DEHYDROGENASE; ISOENZYMES; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE PHOSPHORYLATION;

EID: 84880321156     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2530     Document Type: Article

References (50)

1. Warburg, O., Posener, K. & Negelein, E. On the metabolism of carcinoma cells. Biochem. Z. 152, 309-344 (1924).
2. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
3. Vogelstein, B. & Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004).
4. Vander Heiden, M.G., Cantley, L.C. & Thompson, C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
5. DeBerardinis, R.J., Sayed, N., Ditsworth, D. & Thompson, C.B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18, 54-61 (2008).
6. Hsu, P.P. & Sabatini, D.M. Cancer cell metabolism: Warburg and beyond. Cell 134, 703-707 (2008).
7. Anastasiou, D. et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839-847 (2012).
8. Le, A. et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15, 110-121 (2012).
9. Barrett, T. et al. NCBI GEO: archive for functional genomics data sets-10 years on. Nucleic Acids Res. 39, D1005-D1010 (2011).
10. Parkinson, H. et al. ArrayExpress update-from an archive of functional genomics experiments to the atlas of gene expression. Nucleic Acids Res. 37, D868-D872 (2009).
11. Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M. & Hirakawa, M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355-D360 (2010).
12. Glazko, G. & Mushegian, A. Measuring gene expression divergence: the distance to keep. Biol. Direct 5, 51 (2010).
13. Romero, P. et al. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol. 6, R2 (2005).
14. Koppenol, W.H., Bounds, P.L. & Dang, C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325-337 (2011).
15. Smith, C.A., Moss, J.E., Gough, A.C., Spurr, N.K. & Wolf, C.R. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ. Health Perspect. 98, 107-112 (1992).
16. Khedhaier, A. et al. Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer 8, 109 (2008).
17. Friedman, N. Inferring cellular networks using probabilistic graphical models. Science 303, 799-805 (2004).
18. Faith, J.J. et al. Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol. 5, e8 (2007).
19. Gillies, R.J., Robey, I. & Gatenby, R.A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49 (suppl. 2), 24S-42S (2008).
20. Jolliffe, I.T. Principal Component Analysis, 2nd edn. (Springer, New York, 2002).
21. Duarte, N.C. et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl. Acad. Sci. USA 104, 1777-1782 (2007).
22. Lehninger, A.L., Nelson, D.L. & Cox, M.M. Lehninger Principles of Biochemistry, 5th edn. (W.H. Freeman, New York, 2008).
23. Diaz-Ruiz, R., Uribe-Carvajal, S., Devin, A. & Rigoulet, M. Tumor cell energy metabolism and its common features with yeast metabolism. Biochim. Biophys. Acta 1796, 252-265 (2009).
24. Christofk, H.R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008).
25. Walenta, S., Schroeder, T. & Mueller-Klieser, W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr. Med. Chem. 11, 2195-2204 (2004).
26. Estrela, J.M., Ortega, A. & Obrador, E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43, 143-181 (2006).
27. Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765 (2009).
28. Cheng, T. et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl. Acad. Sci. USA 108, 8674-8679 (2011).
29. Asaka, M. et al. Alteration of aldolase isozymes in serum and tissues of patients with cancer and other diseases. J. Clin. Lab. Anal. 8, 144-148 (1994).
30. Kusakabe, T., Motoki, K. & Hori, K. Human aldolase C: characterization of the recombinant enzyme expressed in Escherichia coli. J. Biochem. 115, 1172-1177 (1994).
31. Swinnen, J.V., Brusselmans, K. & Verhoeven, G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 9, 358-365 (2006).
32. Costello, L.C. & Franklin, R.B. Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. Horm. Metab. Res. 34, 417-424 (2002).
33. Evans, C.T., Scragg, A.H. & Ratledge, C. A comparative study of citrate efflux from mitochondria of oleaginous and non-oleaginous yeasts. Eur. J. Biochem. 130, 195-204 (1983).
34. Metallo, C.M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384 (2012).
35. Dang, L., Jin, S. & Su, S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol. Med. 16, 387-397 (2010).
36. Frezza, C., Pollard, P.J. & Gottlieb, E. Inborn and acquired metabolic defects in cancer. J. Mol. Med. 89, 213-220 (2011).
37. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
38. Zou, Y. et al. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem. Biophys. Res. Commun. 402, 378-383 (2010).
39. Isaacs, J.S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153 (2005).
40. Koivunen, P. et al. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J. Biol. Chem. 282, 4524-4532 (2007).
41. Hewitson, K.S. et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J. Biol. Chem. 282, 3293-3301 (2007).
42. Habano, W. et al. Reduced expression and loss of heterozygosity of the SDHD gene in colorectal and gastric cancer. Oncol. Rep. 10, 1375-1380 (2003).
43. Bass, A.J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 43, 964-968 (2011).
44. Wood, L.D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
45. Segre, D., Vitkup, D. & Church, G.M. Analysis of optimality in natural and perturbed metabolic networks. Proc. Natl. Acad. Sci. USA 99, 15112-15117 (2002).
46. Zu, X.L. & Guppy, M. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 313, 459-465 (2004).
47. Wu, Z. & Irizarry, R.A. Preprocessing of oligonucleotide array data. Nat. Biotechnol. 22, 656-658, author reply 658 (2004).
48. Smyth, G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, e3 (2004).
49. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B Met. 57, 289-300 (1995).
50. Stratton, M.R., Campbell, P.J. & Futreal, P.A. The cancer genome. Nature 458, 719-724 (2009).